

**STATE OF HAWAII  
REQUEST FOR SOLE SOURCE**

STATE PROCUREMENT OFFICE  
STATE OF HAWAII

TO: Chief Procurement Officer

FROM: Department of Health/State Laboratories Division/Medical Microbiology Branch

Pursuant to §103-306D, HRS, and Subchapter 9, Chapter 3-122, HAR, the Department requests sole source approval to purchase the following:

<p>Description of goods, services, or construction:</p>   <p align="center"><b><u>Human Immunodeficiency Virus EIA Test Kits</u></b></p>
---

<p>Name of Vendor: <b><u>Bio-Rad Laboratories (Genetic Systems)</u></b></p> <p>Address: 1000 Alfred Nobel Drive Hercules, CA 94547</p>	<p>Cost: <b><u>Ninety Thousand Dollars (\$ 90,000).</u></b></p>
--	---

<p>Term of Contract: From: <del>October 15, 2005</del> To: <b><u>October 14, 2006</u></b></p> <p align="center">Upon CPO Approval</p>	<p>Prior Bid Exemption Reference No.(s) 05-20-J, 04-12-J, 03-35-R, 02-22J, 01-21R, 00-14R, 99-24-J, 98-52-R, 97-53-J, 95-220-R, 94-588-J, 93-500-R, 92-351, 91-17.</p>
---	--

<p>The goods, services, or construction has the following unique features, characteristics, or capabilities:</p> <p>The test kits to be purchased are <b>USFDA</b> approved for the screening of human serum or plasma for antibodies to the Human Immunodeficiency Virus (HIV), Type 1 and Type 2. These agents have been identified as the causative agents of Acquired Immune Deficiency Syndrome (AIDS). For many years, test kits were developed and marketed to detect HIV-1. Several years ago, with the discovery of a second HIV, newer test kits for this second virus were developed. Currently, test kits come in an individual format, in which each type of HIV can be tested separately, and a combination format, in which both agents can be tested for in one procedure. This product, from Bio-Rad Laboratories, who acquired the Sanofi Diagnostics Pasteur, is marketed by their Genetic Systems division, uses a peptide antigen. The use of this type of antigen is believed to yield sensitive results, without a large number of false positives.</p> <p>The diagnostic algorithm, used in the nation's public health laboratories, for testing for HIV, requires the screening of all specimens by an Enzyme Immunoassay (EIA) procedure. Any initial screen positives, are repeated in duplicate, to rule out technician error, and if found positive, a supplemental test is performed. The use of the individual test format would require each specimen to be tested for each type and repeated if found positive. The</p>
--

